Tips

九月美迪西將主辦2場線上直播，同時參與15場海內外行業會議，期待與各位業內同仁交流分享藥物研發新趨勢。

第十二屆藥物毒理學年會

由中國藥理學會藥物毒理專業委員會主辦的“第十二屆藥物毒理學年會”將于2024年9月1日至3日在上海市光大會展中心召開。

為推動毒理學前沿研究進展和成果轉化，美迪西專家將從一般毒理學、先進治療藥物、藥物GLP規范與質量保證等研究方向，在相應主題分會場帶來3場精彩演講，同時展出1項研究壁報，希望通過此次重要的毒理學術盛會，與行業專家深入交流和分享最新的研究成果。

EFMC-ISMC 2024

The XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024) is organised by the Medicinal Chemistry Division of Italian Chemical Society, on behalf of the European Federation for Medicinal chemistry and Chemical biology (EFMC). The symposium will take place in Rome, Italy from September 1-5, 2024. The EFMC is the main organisation for the European Medicinal Chemistry and Chemical Biology community, with 30 member societies and about 9.000 members. Its biennial EFMC-ISMC is a key symposium in the field of medicinal chemistry and drug discovery, and it traditionally attracts around 1.000 participants both from industry and academia. The scientific programme of EFMC-ISMC 2024 will furthermore cover a wide range of selected topics with parallel sessions split into three main themes: 1) Chemical Biology; 2) Drug Discovery Pojects; 3) Technologies.

Medicilon is thrilled to exhibit in the conference. Dr. Paul van Stralen, VP of Strategic Collaborations EMEA at , will be available throughout the conference. We invite you to visit us at Medicilon Booth #6 to explore our services and capabilities.

EUROTOX 2024

We are pleased to announce that Medicilon will exhibit in the EUROTOX 2024 with the Booth #43. The congress will take place from 8 to 11 September 2024 at Copenhagen, Denmark. The congress theme “Toxicology - A Quest for safe Chemicals and Medicines” reflects the congress programme including a variety of topics dealing with safety of drugs and environmental chemicals, new and emerging technologies, personalised medicine, human health effects caused by exposure to chemicals as well as safety issues arising from climate changes. Dr. Renzong Xie, Vice President of Medicilon Quality Assurance Department, and Medicilon team will be present throughout the conference. Please stop by at our booth and discuss how Medicilon’s services and capabilities could support your research needs and expedite your drug discovery and development process.

PBSS Workshop

The landscape of disease-treatment modalities has undergone a dramatic transformation in recent years. New therapeutic modalities, with innovative mechanisms of action, are revolutionizing patient care. Some of these advancements extend beyond traditional small molecules and antibodies to encompass exciting areas like bispecific antibodies, ADCs and gene therapies. Even within the small molecule realm, covalent binders, biased agonists and pan-inhibitors are pushing the boundaries of our understanding of pharmacokinetic (PK)/pharmacodynamic (PD) relationships. In addition to this, therapeutics that are intended for ocular and neuro delivery put forth challenges associated with delivering desired drug concentrations at the site of action. Medicilon team will be present throughout the event.

2024香港國際生物科技論壇展覽 

BIOHK 2024第三屆香港國際生物科技論壇暨展會作為香港生物科技展會的標桿展會，將于9月11-14在香港會展中心召開。

美迪西團隊將在3E-C10號展位等待業界同仁的光臨！

2024第三屆國際生物醫藥產業發展大會 

以“增進跨文化創新，保障世界永續健康”為主題的第三屆國際生物醫藥產業發展大會，將于2024年9月12-14日在上海舉辦。

? 美迪西首席科學館彭雙清教授將擔任美迪西英才“山海會”圓桌論壇主持人，并參與高端對話環節；

? 美迪西制劑部高級主任&新藥注冊部總監王丹博士將出席發表演講；

? 美迪西藥效部項目經理袁云云博士將出席發表演講。

2024 BioSpark Annual Conference

BioSpark will host the 2024 Annual Conference on Saturday, September 14 at Cambridge, MA. The conference theme this year is “Braving through the Winter of Biotech”, and will bring together professionals from the biotech industry to discuss the latest trends and innovations. Whether you're a seasoned expert or just starting out in the field, this event is perfect for anyone looking to stay ahead in the world of biotechnology. Medicilon is excited to attend and exhibit at the conference. Dr. Qingcong Lin, President of Medicilon USA Corp., will give a presentation. Dr. Lin brings nearly 40 years of experience in pharmaceutical R&D, making significant contributions to both academia and the global industry. Medicilon team will be present throughout the event. 

26th North American ISSX and 39th JSSX Meeting

Meet Medicilon at 26th North American ISSX and 39th JSSX Meeting. As the foremost organization representing the interests of researchers and educators in DMPK and other related areas of research, the International Society for the Study of Xenobiotics (ISSX) is engaged in multiple activities to support, promote, and advance the science worldwide.  ISSX has an international base of members from more than 45 countries. Members are comprised fairly evenly between academic and industry groups and consist primarily of research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics. 

During the Conference, Dr. Pin Jiang, Senior Director of DMPK at Medicilon, will present the poster titled "Enhancing Drug-Drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4". Medicilon team will be present throughout the event. 

第八屆全國核酸疫苗大會

中國疫苗行業協會核酸疫苗分會將于2024年9月19日-22日在上海舉辦第八屆全國核酸疫苗大會。本次大會的主題為“砥礪深耕 ·篤行致遠”，熱情邀請全國相關領域專家、學者、科研骨干、企業代表與會交流。

美迪西團隊將在A02號展位等待業界同仁的光臨！

PBSS Workshop

With the advent of complex biologics and the increasing use of novel modalities over traditional antibodies during drug development, it has become critical to develop our understanding on their unique safety assessments and challenges. The intent of this workshop is to enlighten to develop an understanding of toxicity risk assessments and share latest progress in the field of biologics to activate discussions that will lead to more successful IND/BLA submissions. Medicilon team will be present throughout the event.

BioForward 2024

Meet Medicilon at BioForward 2024! BioForward is OBN's 'Roadmap for Growth' Life Sciences event, designed to provide the support, skills, know-how and industry connections required to catalyse the growth of your company. Now in its sixth year, BioForward is attended by leaders and decision makers of growing R&D companies across all therapy and technological areas, alongside companies who provide the specialist services, products, advice and expertise essential for all companies as they grow. Medicilon is excited to attend and exhibit at the conference. Dr. Wenjie Li, Vice President of the CMC Unit at Medicilon, PARTNERING WITH THE RIGHT MANUFACTURER TO ACCELERATE YOUR RESEARCH" at 14:35-14:55 local time during Workshop Session 6 - Partnering with the right manufacturer to accelerate your research.

第九屆國際藥物研究與發展新興技術大會（IAPC-9）

IAPC-9由國際物理化學家協會、ADMET 和 DMPK Journal 主辦，北京大學藥學院、上海交通大學藥學院、美迪西和騰邁聯新聯合主辦。此次會議的中心主題是“藥物發現和開發的新興技術”，旨在傳播和分享藥物發現和開發領域的新技術和前沿平臺。

美迪西作為本次大會的協辦單位，將全程在展位等待業界同仁的光臨！

第三屆BIONNOVA北京創新論壇

時維九月，春華秋實，第三屆BIONNOVA北京創新論壇將于朗麗茲西山花園酒店開啟全新篇章！

美迪西首席科學官彭雙清教授將出席發表演講，同時美迪西團隊將全程設展，期待與 您再次相會！

2024 SAPA Annual Conference

Sino-American Pharmaceutical Professionals Association (SAPA) will host the 2024 Annual Conference on Friday & Saturday, September 27 & 28 at Hyatt Regency New Brunswick, 2 Albany St, New Brunswick, New Jersey. The conference theme this year is “Redefining Medicine: Navigating Resilience, Transforming Lives”, and will include plenary sessions and 7 panel discussions such as Investment/Business Development, Drug Discovery, CMC, Clinical Development/Regulatory, Career Development, Executive/Legal, Artificial Intelligence (AI), and plenty of networking opportunities.  During the SAPA SAPA Annual Conference, Dr. Wenjie Li, Vice President of the CMC Unit at Medicilon, will participate in the panel discussion "CMC and Outsourcing". Dr. Qingcong Lin, President of Medicilon USA Corp., and Medicilon team will be present throughout the conference. 

DOT 2024

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. DOT 2024 four-day event brings back popular topics like kinases, immunomodulation, and degraders, plus new coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models. We looks forward to meeting you from September 30-October 3 in Boston, MA. Medicilon is experienced with oncology drug in any preclinical phases, from hit-to-lead to IND. We provide integrated service strategies for sponsors’ oncology drug discovery and development pipelines. We aim to enhance every step in preclinical search and to deliver real time data.

marketing@medicilon.com.cn媒體與會務請聯系
美迪西市場部微信或郵箱